Company ProfilePremium

Bacil Pharma Limited

Company Profile Analysis

Ticker: 524516.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bacil Pharma Limited - Company showcase

Year Founded & Workforce

1987

Bacil Pharma Limited logo

Bacil Pharma Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bacil Pharma Limited Overview

Bacil Pharma Limited is a 39-year-old Mumbai-incorporated company that is formally classified as a pharmaceutical manufacturer (pharmaceuticals, medicinal chemicals and botanical products) but has reported no revenue from operations in any year from FY2015 through FY2026. Its income is entirely "other income", mainly returns on a treasury and investment book of about ₹21 Cr created when the company raised about ₹24 Cr through a preferential allotment in FY2025. Since then, the original Shah promoter family has exited and control has passed to a new board led by Managing Director and CFO Chaitali Kalpataru Shah. Under this board the company has set up an R&D subsidiary, approved a rights issue of up to ₹50 Cr, and raised authorised capital to ₹70 Cr. In economic terms Bacil is best described as a listed shell undergoing a proposed revival into pharmaceuticals. Its equity has been highly volatile, falling about 53% over the past year.


Company's own description

In its FY2025 Management Discussion & Analysis (dated 5 September 2025), the company describes itself as primarily engaged in healthcare solutions. It says its focus is the development, manufacturing and distribution of pharmaceutical formulations: tablets, capsules, ointments, injectables and specialty products. The same MD&A acknowledges that the company earned no revenue from its core business in FY2025. It attributes the year's improvement in financial position to higher other income and cost control. Management states it is looking at operational expansion, revenue generation in core pharmaceutical verticals, further investment opportunities and product innovation. Aggregators describe the business as manufacturing and selling pharmaceuticals, medicinal chemicals and botanical products (Value Research, Tickertape). Trendlyne describes it as offering herbal extracts, heavy, medium and fine chemicals, and bulk intermediates. The MCA lists its principal activity as "Manufacture of Chemicals and Chemical Products".

Independent characterisation

The filings do not support the company's description of itself as an operating pharmaceutical business:

  • Revenue from operations has been nil in every reported year from FY2015 to FY2026 (Screener.in 12-year P&L). Capital Market reports state there were no sales in Q4 FY2026 or FY2026 as a whole, and none in Q1 FY2027.

Fixed assets were about ₹1 lakh at FY2024 and nil at FY2025: (IIFL balance sheet). No manufacturing plant, inventory or trade receivables appear on the balance sheet.

Inventory and debtors have been zero: in FY2022–FY2025.

  • The company's assets are almost entirely financial investments (₹21.36 Cr) and cash (₹2.86 Cr) at 31 March 2025.

Bacil Pharma is therefore, in substance, a listed corporate shell with a treasury book. Its income comes from interest, dividends and gains on investments. The investment thesis depends entirely on whether the new management can build or acquire a pharmaceutical operation using the planned rights issue proceeds.

Revenue model and mix

Revenue typeFY2025 shareFY2026 shareComment
Product sales0%0%No operating revenue reported
Services0%0%None reported
Subscription / licensing0%0%None reported
Other income (treasury/investment)100%100%₹66.14 lakh in FY2025 (Directors' Report); about ₹122 lakh in FY2026 (derived)

Value-chain position, customers and end-markets

Value-chain position: None in practice. The intended position is formulations manufacturing and distribution (per MD&A), but no plant, licences or distribution network is disclosed.

Customer types: Not publicly disclosed. There were no customers in FY2025–FY2026.

End-markets: Intended: the Indian domestic formulations market. Actual: none.

Data-integrity warning: Several broker profiles (ICICI Direct and others) describe "Bal Pharma Institutional division" and "Bal Pharma Units 1, 2 and 3" making tablets, APIs and IV fluids under the Bacil Pharma page. This text belongs to Bal Pharma Ltd, a different company, and is a data-vendor error. It should not be attributed to Bacil Pharma.

Strategy

Stated strategy (themes from FY2025 MD&A, paraphrased)

  • Keep a conservative and prudent approach to operations.

  • Look at future business opportunities that could generate sustainable operating revenue.

  • Explore operational expansion and revenue generation in core pharmaceutical verticals.

  • Pursue further investment opportunities and product innovation.

  • Value human capital (no headcount disclosed).

No investor day has been held and no medium-term financial targets have been published.

Initiatives announced in the last 24 months

DateInitiativeDetailStatusSource
FY2025Preferential equity raiseAbout ₹24 Cr at ₹32 per share to non-promoters; 85 lakh shares cleared for listing on 3 Jun 2025CompletedTiger Brokers; IIFL
18 Jun 2026R&D subsidiaryProposal for a wholly owned R&D companyIncorporated 28 Jul 2026ScanX
26 Jun 2026Fund-raising frameworkUp to ₹50 Cr via rights, preferential issue, convertibles or warrantsSuperseded by rights decisionWhalesbook
9–11 Jul 2026Rights issueUp to ₹50 Cr of equity sharesApproved by board; no letter of offer, price or record date disclosedScanX; Groww
23 Sep 2026Authorised capital increaseTo ₹70 Cr (from ₹8 Cr in MCA records)Approved by shareholdersScanX
Sep–Oct 2026Debt financing₹5.52 Cr consolidated borrowings appear at 30 Sep 2026Terms not disclosedWhalesbook

Sustainability/ESG commitments: None disclosed.

Cost programmes: None beyond general "cost control" (MD&A FY2025).

Guidance: None.

Assessment. The strategy is a capital-raising plan without a disclosed operating plan. The proposed ₹50 Cr rights issue is about 1.7× the current market capitalisation of about ₹29 Cr. No project report, product pipeline, acquisition target or facility plan has been filed to explain the use of proceeds.

Products & Services

Assessment. No named brands, registered drug formulations, DCGI/FDA product licences, ANDAs or dossiers are disclosed in any source reviewed. The "portfolio" in company documents is a list of dosage-form categories, not a product catalogue. No flagship offering exists.

Product Portfolio

Product line / brandDescriptionSpecificationsTarget customerLaunch / latest versionPricingStatus

Tablets

Named in MD&A as a formulation category

————

No sales recorded FY2015–FY2026

Capsules

Named in MD&A

————

No sales recorded

Ointments

Named in MD&A

————

No sales recorded

Injectables

Named in MD&A

————

No sales recorded

Specialty products

Named in MD&A

————

No sales recorded

Herbal extracts / botanical products

Listed in aggregator descriptions (Trendlyne, Value Research)

——

Historical

—

No sales recorded

Heavy, medium and fine chemicals; bulk intermediates

Listed in Trendlyne description, probably reflecting the pre-2015 business

—

Industrial buyers (historical)

Historical

—

No sales recorded

“—” = not publicly disclosed.

Financial Narrative

Income statement (standalone, INR lakh)

Sources and notes: - Total income FY2022–FY2023: Tickertape (₹0.06 Cr and ₹0.11 Cr). FY2024–FY2025: FY2025 Directors' Report. FY2026 is derived (quarterly PBT sum ₹0.97 Cr plus expenses about ₹0.25 Cr).

  • Expenses: Screener.in annual expense row (₹0.16, 0.17, 0.19, 0.25, 0.25 Cr). FY2022–FY2023 PBT is derived as income minus expenses.

  • Depreciation and finance costs are approximately nil (Fyers), so EBITDA approximately equals PBT.

  • FY2024 PAT: the Directors' Report shows ₹11.38 lakh profit after tax (probably after a deferred-tax credit), while Fyers/Torus show a loss of ₹5.91–6 lakh. The movement in reserves (−₹5.43 Cr to −₹5.31 Cr) supports the ₹11 lakh figure.

  • FY2025 PAT: ₹40.05 lakh (Directors' Report) vs ₹40.42 lakh (Fyers). EPS of ₹0.30 is from Fyers.

  • FY2026 PAT: Capital Market reports net profit of ₹1.56 Cr (+290%). ScanX instead reports a "net loss of ₹61.88 lakh" vs ₹6.17 lakh the prior year. Analyst reconciliation: the ScanX numbers appear to be total comprehensive income, i.e. after other comprehensive income (OCI) fair-value losses on investments. Supporting evidence: Screener's book value of ₹17.3 per share at March 2026 implies net worth of about ₹24.8 Cr, which is below FY2025's ₹25.43 Cr despite a ₹1.56 Cr PAT. That implies an OCI loss of about ₹2.2 Cr. FY2026 EPS of about ₹1.09 is derived from Screener's P/E of 45.4 at ₹49.4.

  • Q4 FY2026: PAT ₹0.62 Cr (Capital Market) vs a ₹164.14 lakh loss (ScanX), consistent with the same PAT/TCI distinction.

Commentary. The P&L has no operating engine. From FY2022 to FY2024, interest on a cash balance of about ₹1 Cr did not cover listing and administrative costs of ₹16–19 lakh. The FY2025 inflection is purely balance-sheet driven: the roughly ₹24 Cr preferential raise was invested, and other income rose about five times to ₹66 lakh. FY2026 PAT rose again to about ₹1.56 Cr, but Q1 FY2026 alone contributed ₹0.67 Cr. That points to lumpy realised gains rather than recurring yield. Mark-to-market losses booked through OCI turned comprehensive income negative. In FY2027 to date, income has collapsed: H1 FY2027 total income was ₹0.18 Cr vs ₹1.06 Cr in H1 FY2026 (Whalesbook), and the company is back to losses.

Margins. Gross, operating, EBITDA and net margins on operating revenue are not meaningful because the denominator is zero. Aggregator "net margin" figures (for example, 563.64% for Q4 FY2026 on IndMoney) are computed on other income and should be disregarded.

Revenue CAGR (FY2022–FY2026): Not meaningful for operating revenue. Total-income CAGR is about 113% (derived), but this reflects a capital injection, not organic growth.

Balance sheet (standalone, INR lakh)

Sources: IIFL/IndiaInfoline standalone balance sheet FY2022–FY2025. FY2026 total assets ₹2,739.26 lakh (ScanX, from the FY2026 audited results; FY2025 shown there as ₹2,560.02 lakh). FY2026 cash ₹0.57 Cr and nil borrowings (Whalesbook, Q2 FY2027 results comparison). FY2026 equity derived from Screener book value ₹17.3 × about 1.435 crore shares.

Conflict: MarketsMojo shows Mar 2024 share capital of ₹23.71 Cr and shareholders' funds of ₹24.65 Cr. This is inconsistent with IIFL (₹6.53 Cr / ₹1.22 Cr) and with the reserve trajectory. IIFL is treated as correct.

Post-period development. As of 30 September 2026, consolidated borrowings were ₹5.52 Cr (vs nil at 31 March 2026) and consolidated cash was ₹0.97 Cr (Whalesbook). The lender, terms and use of the borrowing are not publicly disclosed. This is the company's first material debt in the available record.

Cash flow (INR lakh)

Cash-flow statements are not available in the sources reviewed. FY2025 equity raised is derived: increase in share capital of ₹7.44 Cr plus about ₹16.4 Cr of share premium (7.44 million shares × ₹22) ≈ ₹23.8 Cr. Capex is inferred as nil from the absence of fixed-asset additions.

Ratios

ROE/ROA are derived on average equity/assets. The FY2026 ROE of 6.2% matches Screener's reported 6.21%, and FY2026 ROCE of 3.93% is from Screener. MarketInOut reports ROE 5.26%, ROA 5.06% and ROIC −0.97% on a trailing basis. Interest coverage is not meaningful (negligible finance cost). The cash conversion cycle is not applicable (no inventory, receivables or payables).

Interpretation. Returns are thin. A 6% ROE in FY2026, earned on a treasury book, is below the yield of an Indian government bond. Because operating ROIC is negative, every rupee of administrative cost depends on investment income. The balance sheet was conservative (debt-free at FY2026), but the new ₹5.52 Cr consolidated borrowing changes that profile.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

SegmentFY2024FY2025FY2026

Pharmaceuticals: revenue from operations (INR Lakh)

000

Other income, non-segment (INR Lakh)

1366122

Segment pre-tax result (INR Lakh)

-64197

Contribution of pharma segment to total revenue (%)

000

Group Entities

EntityRelationshipIncorporatedActivitySource

Bacil Pharma Limited

Listed parent

1987

Holding/treasury; intended pharma formulations

BSE

Bacil Research & Development Pvt Ltd

Wholly owned subsidiary

28 Jul 2026

Pharmaceutical R&D (stated intent)

ScanX

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Lakh)

00000

Total income incl. other income (INR Lakh)

6111366122

Total expenses (INR Lakh)

1617192525

Gross profit (INR Lakh)

00000

Operating income ex-other income (INR Lakh)

-16-17-19-25-25

EBITDA incl. other income (INR Lakh)

-10-6-64197

Pre-tax income (INR Lakh)

-10-6-64197

Net income, PAT (INR Lakh)

——1140156

Total comprehensive income (INR Lakh)

———-6-62

EPS basic (INR)

———0.301.09

Dividend per share (INR)

00000

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Lakh)

1261131372,5602,739

Cash and equivalents (INR Lakh)

233428657

Investments (INR Lakh)

3143612,136—

Total debt (INR Lakh)

3210160

Net debt (INR Lakh)

-20-16-270-57

Equity share capital (INR Lakh)

6536536531,397—

Reserves (INR Lakh)

-530-543-5311,146—

Shareholders' equity (INR Lakh)

1231101222,5432,483

Goodwill and intangibles (INR Lakh)

0000—

Net working capital (INR Lakh)

605459132—

Fixed assets (INR Lakh)

1110—

Balance Sheet — Capital expenditure

MetricFY2022FY2023FY2024FY2025FY2026

Capital expenditure (INR Lakh)

0000—

Equity raised (INR Lakh)

0002,380—

Dividends paid (INR Lakh)

00000

Buybacks (INR Lakh)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE (%)

——9.53.06.2

ROA (%)

——8.73.05.9

ROCE (%)

————3.9

Debt to equity (x)

0.020.020.080.010.00

Net debt to EBITDA (x)

———-6.6-0.6

Asset turnover on operating revenue (x)

00000

Results by Region

RegionFY2024FY2025FY2026

India: revenue from operations (INR Lakh)

000

Outside India: revenue from operations (INR Lakh)

000

India: total income incl. other income (INR Lakh)

1366122

Share Price History

DatePrice (INR)Market cap (INR Cr)Source

4 Aug 2025

37.58—

Trendlyne

26 Dec 2025

34.23—

ICICI Direct

2 Jan 2026

38.3555

Business Standard

2 Apr 2026

52.60—

ICICI Direct

27 May 2026

51.0973

Value Research

3 Jun 2026

48.0172.22

Torus Digital

9 Jul 2026

38.3655.06

IIFL

7 Aug 2026

16.9324.30

IIFL

14 Aug 2026

13.12—

ICICI Direct

~19–20 Oct 2026

20.34

~29 (derived)

ScanX

Share Price & Returns

HorizonReturnAs ofSource

1 month

−3.60%

Oct 2026

ScanX

6 months

−62.59%

Oct 2026

ScanX

1 year

−52.97%

Oct 2026

ScanX

3 years (CAGR)

+25.20%

7 Aug 2026

IIFL

5 years (CAGR)

+21.79%

7 Aug 2026

IIFL

Valuation Multiples

MultipleBacil PharmaPeer referenceComment

P/E (FY2026 EPS about ₹1.09)

~18.7×

Peer median about 47× (Value Research, May 2026)

EPS is non-operating and non-recurring

P/B (book about ₹17.3)

~1.2×

Peer median about 3.9× (Value Research, May 2026)

Book is mostly investments, marked to market

Capital Markets

ItemDetail

Analyst consensus

None (0 analysts, Simply Wall St)

Dividend history / policy

No dividend paid in the record; no stated policy

Credit ratings (Moody's / S&P / Fitch / domestic)

Not rated

Debt maturity profile

Not disclosed (₹5.52 Cr consolidated borrowings at 30 Sep 2026)

Beta

−0.085 (Snowball) to 0.47 (Simply Wall St); not reliable given illiquidity

Liquidity

BSE-only; daily volumes about 20,000–1,44,000 shares in sampled sessions (Fyers; Trendlyne)

Circuit band

Frequent 5% moves (for example −5.00% on several sampled days), consistent with a narrow price band

Analyst Conclusions

Management guidance and consensus

Guidance: None issued. Management's stated intent (FY2025 MD&A) is to explore operational expansion and revenue in core pharmaceutical verticals.

Consensus: No analyst coverage, so no consensus growth expectations exist.

Bull case

  1. Capital plus listing equals an option value. With about ₹21 Cr of investments (FY2025) and a ₹50 Cr rights issue authorised, Bacil could fund a small formulations or loan-licence business, or merge in an operating company. The stock trades at about 1.2× a book made up mostly of liquid assets.

  2. The board has a clear shareholder mandate. Approval of 99.93–100% for all resolutions, and the creation of an R&D subsidiary, suggest a coordinated plan is being executed.

  3. The de-rating may have overshot. A fall of about 63% in six months took the price to roughly book value. Any credible announcement of an operating plan or acquisition could re-rate the stock from a low base, as the 3-year CAGR of 25% shows it has done before.

Bear case

  1. No business, collapsing income. Nil sales for 12 years and H1 FY2027 income down 83% leave a shell burning cash. The ₹5.52 Cr of new borrowings adds leverage with no visible earning asset.

  2. Dilution and governance risk. A rights issue of up to 1.7× the market cap, the absence of a classified promoter, a vacant compliance officer post, a revised quarterly result and GSM surveillance create a high-risk governance profile.

  3. Earnings quality is poor. FY2026 PAT (+₹1.56 Cr) and total comprehensive income (−₹0.62 Cr) diverge, which suggests reported profits overstate economic value creation. Book value fell year on year.

Catalysts and monitorables (next 12 months)

MonitorableWhat to watch
Rights issueFiling of the letter of offer; price, ratio, record date; use of proceeds; subscription levels
Use of borrowingsDisclosure of lender, terms and purpose of the ₹5.52 Cr
Operating planAny plant acquisition, loan-licence agreement, product registrations or acquisition target
R&D subsidiaryCapitalisation, staffing, research agenda
ComplianceAppointment of a new CS within the statutory window; quarterly filings on time
ControlSAST filings; any promoter reclassification or open offer
SurveillanceGSM stage changes and any further BSE queries
ResultsQ3 FY2027 (due around February 2027) and FY2027 audited results (May 2027): income, OCI, borrowing levels

Analyst verdict

Bacil Pharma Limited is not, on the evidence of its own filings, a pharmaceutical company in any operating sense. It is a 1987-vintage BSE shell. It has reported no revenue from operations for twelve consecutive fiscal years, owns no fixed assets, and holds about ₹21–27 Cr of financial assets that came almost entirely from a FY2025 preferential allotment at ₹32 per share. Since then the founding Shah promoter family has sold out and a new board under MD and CFO Chaitali K. Shah has taken over. That board has created an R&D subsidiary, approved a rights issue of up to ₹50 Cr and raised authorised capital to ₹70 Cr. However, it has not disclosed a product pipeline, facility, licence, partner or acquisition that would turn this capital into an operating business.

The financial record argues for caution. FY2026 reported profit of about ₹1.56 Cr depended on treasury gains, and total comprehensive income was negative because of investment write-downs. H1 FY2027 income fell by more than 80%, the company returned to losses, and it took on ₹5.52 Cr of borrowings with undisclosed terms. Governance signals point the same way: the compliance officer post has been vacant since October 2026, a director-appointment intimation was withdrawn, a quarterly result was revised, auditors were changed, and the stock is under exchange surveillance. The share price has fallen about 53% in a year and about 63% in six months, and it now trades near book value.

The only real source of value is optionality: a listed, debt-light platform that a credible sponsor could use to build or inject a business. Until management files a rights offer document with a specific, verifiable use of proceeds, the shares are best treated as a speculative, governance-sensitive special situation rather than a pharmaceutical investment. Fundamental valuation is not meaningful, and the main risk to an investor is losing capital through dilution and leakage of the investment book.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleDINTenure / appointmentPrior rolesSource

Chaitali Kalpataru Shah

Managing Director and CFO (redesignated from Executive Director at the 39th AGM, 23 Sep 2026)

11,167,778

Director since c.2025 (exact date not disclosed); MD from Sep 2026

—

ScanX AGM report

Omprakash Pyarelal Sonar

Independent Director (reappointed at 39th AGM)

11,031,877

c.2025 onward

—

ScanX

Vivek Mukesh Yadav

Independent Director (reappointed at 39th AGM)

11,033,957

c.2025 onward

—

ScanX

Mahesh Singh

Independent Director (appointed 25 Aug 2026; regularised at AGM)

11,814,569

Since Aug 2026

—

ScanX; Groww

Anil (Shiv Charan) Singh

Non-Executive Non-Independent Director (appointed 25 Aug 2026; regularised at AGM)

09,338,444

Since Aug 2026

An "Anil Singh" is listed as a director of Baxil Pharma Pvt Ltd (Delhi). Whether this is the same person is unconfirmed

ScanX; InsiderBiz

Company Secretary & Compliance Officer

Vacant since 8 Oct 2026 (Dikshant Singh Panwar resigned, citing personal and professional commitments)

———

ScanX

“—” = not publicly disclosed.

Board of Directors — Prakash Bhoorchand Shah

NameFormer roleExitSource

Prakash Bhoorchand Shah

Promoter / Director

Sold shares 2024–25; promoter group exited by Mar 2026

Companydetails.in; Simply Wall St

Suman Prakash Shah

Promoter / Director

Disposed of entire stake (FY2026)

ScanX; Companydetails.in

Mehul Hasmukhbhai Shah

Executive Director

Resigned 24 Feb 2025

Directors' Report FY2025

Ganpat Dhondu Salekar

Manager

—

Vogue Commercial

Bhavana Tak

Company Secretary & Compliance Officer

—

Vogue Commercial

Shirish Suryakant Shetye; Lalit Jain; Jayesh Ramchandra Patil

Directors (historical)

—

Companydetails.in

Avani Savjibhai Godhaniya

Proposed Independent Director (effective 9 Jul 2026)

Status unclear after withdrawal and re-proposal of appointments

ScanX

“—” = not publicly disclosed.

Major Shareholders

HolderStakeDate of dataSource

Promoter & promoter group

0% (Torus: fell from 0.08% in Dec 2025 to 0% in Mar 2026). Conflict: Angel One shows 10.6% promoter holding, possibly reflecting reclassification of new controllers or stale data

Mar 2026

Torus Digital; Angel One

Nikita Hiren Patel

10.07% (14,44,844 shares) after selling 7.10%

24 Jun 2026

Whalesbook

Niraj Rajnikant Shah

6.44% (9,25,000 shares)

24 Jun 2026

Whalesbook

GB Logistics Commerce Limited

6.18% (8,87,300 shares)

Date not stated (2025)

Simply Wall St

Parikshit Notaria

1.16%2025

Simply Wall St

Saroj Mehta

1.16%2025

Simply Wall St

Randeep Singh

0.84%2025

Simply Wall St

Manubhai Shah

0.72%2025

Simply Wall St

Gaurang Shah

0.66%2025

Simply Wall St

Jayesh Patel

0.54%2025

Simply Wall St

Navin Mehta

0.43%2025

Simply Wall St

FIIs / DIIs / mutual funds

0% / 0% / 0%

2026

Angel One

Retail / public

About 89.4%

2026

Angel One

Competitive Landscape

Key Competitors

CompanyExchangeRelevanceSource for peer listing

Godavari Drugs

BSE

Micro-cap pharma peer

Business Standard

Lasa Supergenerics

BSE/NSE

Micro-cap API peer

Business Standard

Vasundhara Rasayans

BSE

Micro-cap chemicals peer

Business Standard

Welcure Drugs & Pharmaceuticals

BSE

Micro-cap shell-like pharma peer

Business Standard

Biofil Chemicals & Pharmaceuticals

BSE

Micro-cap pharma peer

Business Standard

Vista Pharmaceuticals

BSE

Micro-cap pharma peer

Business Standard

Fredun Pharmaceuticals

BSE

Small formulations peer

Nirmal Bang

Sun Pharmaceutical Industries

NSE/BSE

Aspirational formulations leader

Tickertape peer list

Cipla

NSE/BSE

Formulations leader

Tickertape

Dr. Reddy's Laboratories

NSE/BSE

Formulations leader

Tickertape

Mankind Pharma

NSE/BSE

Domestic formulations leader

Tickertape

Zydus Lifesciences

NSE/BSE

Formulations leader

Tickertape

Peer Comparison FY2026

MetricBacil Pharma FY2026Typical BSE micro-cap pharma shell

Operating revenue (INR Cr)

0

Often nil to low single digits

Operating margin

Not meaningful (negative opex)

—

R&D intensity

Not disclosed (negligible)

—

Company Snapshot

1987

Founded

SWOT Analysis

Strengths

  • Debt-free at FY2026: borrowings were nil at 31 March 2026 (Whalesbook comparison) and only ₹16 lakh at FY2025 (IIFL).
  • Investment corpus: ₹21.36 Cr of investments and ₹2.86 Cr of cash at FY2025 (IIFL) give it capital to deploy.
  • Positive PAT for three consecutive years: ₹11 lakh (FY2024), ₹40 lakh (FY2025) and ₹1.56 Cr (FY2026, Capital Market).
  • Lean cost base: total annual expenses of about ₹25 lakh (Screener FY2025–FY2026).
  • Clean related-party record: nil RPTs disclosed for H2 FY2026 (ScanX, 22 May 2026).
  • Shareholder support for the new board: 99.93%–100% approval on all nine resolutions at the 39th AGM (ScanX).

Weaknesses

  • Nil operating revenue every year FY2015–FY2026 (Screener).
  • No physical assets: fixed assets nil at FY2025 (IIFL).
  • Earnings quality: FY2026 PAT of ₹1.56 Cr against total comprehensive income of −₹61.88 lakh (Capital Market vs ScanX) points to mark-to-market investment losses.
  • Lumpy income: Q1 FY2026 PAT of ₹0.67 Cr against Q2 FY2026 PAT of ₹0.01 Cr (Capital Market).
  • Governance gaps: CS vacancy from 8 Oct 2026, combined MD/CFO role, and a revised Q3 FY2026 result.
  • No promoter "skin in the game": promoter holding 0% at March 2026 (Torus).

Opportunities

  • Rights issue of up to ₹50 Cr (approved July 2026) could fund an operating platform.
  • R&D subsidiary (incorporated 28 July 2026) is a vehicle for product development or licensing.
  • Authorised capital raised to ₹70 Cr (23 Sep 2026) allows larger capital actions.
  • Listed-platform value: a reverse-merger or acquisition of an operating pharma business is possible (none announced).
  • Price-to-book near 1×: at about ₹20 vs book value of about ₹17.3, a rights issue at or near book would be less dilutive to value.
  • Domestic pharma demand growth benefits any credible new formulation business.

Threats

  • Dilution: a ₹50 Cr rights issue is about 1.7× the current market cap of about ₹29 Cr. Shareholders who do not subscribe face heavy dilution. Shares outstanding already grew about 144% in one year (Simply Wall St).
  • Price collapse and surveillance: the stock fell about 53% over one year and about 63% over six months (ScanX, Oct 2026). It is on GSM (Trendlyne) and drew a BSE price-movement query in February 2026.
  • New leverage: ₹5.52 Cr of consolidated borrowings at 30 Sep 2026, with undisclosed purpose.
  • Income collapse: H1 FY2027 total income of ₹0.18 Cr vs ₹1.06 Cr (Whalesbook).
  • Concentrated, shifting ownership: a 7.10% block sale in June 2026 and multiple 2026 exits near ₹11–20 (Groww; Whalesbook).
  • Regulatory barriers: revised Schedule M GMP requirements raise entry costs for any new manufacturing unit.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Jun 2025BSE listing approval for 85 lakh preferential shares (₹10 face + ₹22 premium) Tiger BrokersCompletes recapitalisation; enlarges float
10 Jul 2025KMP change (details not disclosed) Directors' Report FY2025Management turnover
16 Jul 2025KMP change (details not disclosed) Directors' Report FY2025Management turnover
22 Jul 2025KMP change (details not disclosed) Directors' Report FY2025Management turnover
12 Aug 2025Q1 FY2026: PAT ₹0.67 Cr on other income; nil sales Tickertape/Capital MarketPeak quarterly profit, non-operating
5 Sep 2025Board fixes AGM; FY2025 Directors' Report and MD&A signed IIFL; TorusAdmits nil core revenue
29 Sep 202538th AGM Capital MarketRoutine
13 Nov 2025Q2 FY2026: PAT ₹0.01 Cr (−97.9% YoY) Capital MarketVolatile treasury income
Dec 2025 – Mar 2026Promoter Suman P. Shah disposes of entire stake; promoter holding goes to 0% ScanX; TorusChange of control
13 Feb 2026Q3 FY2026: profit about ₹3.9–6.1 lakh; later revised result filed ScanX; Vogue CommercialRestatement flag
24 Feb 2026BSE seeks clarification on price movement; company cites no undisclosed information ScanXSurveillance attention
22 May 2026FY2026 audited results: PAT ₹1.56 Cr (Capital Market) vs TCI −₹61.88 lakh (ScanX); total assets ₹27.39 Cr HDFC Securities; ScanXEarnings quality question
22 May 2026Nil related-party transactions disclosed for H2 FY2026 ScanXPositive governance datapoint
28 May 2026Annual secretarial compliance report filed; no major non-compliance noted ScreenerCompliance
18 Jun 2026Board proposes wholly owned R&D subsidiary ScanXFirst operating-intent step
22–24 Jun 2026Niraj R. Shah acquires 6.44% in the open market WhalesbookNew substantial holder
24 Jun 2026Nikita H. Patel sells 7.10%, retaining 10.07% WhalesbookLargest holder reduces
26 Jun 2026Board approves exploring a ₹50 Cr fund-raise WhalesbookDilution risk
30 Jun 2026Withdrawal of 29 June director-appointment intimation ScanXGovernance process flag
7 Jul 2026MCA name approval for the proposed subsidiary ScanXProcedural
9–11 Jul 2026Rights issue of up to ₹50 Cr approved ScanX; GrowwMajor capital event
28 Jul 2026Bacil Research & Development Pvt Ltd incorporated ScanXGroup structure created
Jul–Aug 2026Share price falls about 69% over three months to roughly ₹13–17 IIFL; ICICI DirectSevere de-rating
12 Aug 2026Q1 FY2027: net loss ₹1.61 lakh vs ₹0.67 Cr profit a year earlier; nil sales Business Standard; ScanXIncome collapse
19 Aug 2026Jagwani Murlidhar sells 1,16,478 shares at ₹11.38 GrowwHolder exit near lows
25 Aug 2026Mahesh Singh (ID) and Anil S. C. Singh (NED) appointed ScanXBoard reconstitution
28 Aug 2026Brenley Engineers Pvt Ltd buys 84,658 shares at ₹11.67 GrowwCorporate buyer at lows
31 Aug 2026AGM notice: ₹70 Cr authorised capital, MD appointment ScanXPreparation for rights issue
15 Sep 2026Hemang R. Doshi sells 83,531 shares at ₹20.10 GrowwSelling into rebound
23 Sep 202639th AGM: MD redesignation, new auditor, capital increase; all resolutions pass (about 54 lakh votes cast) ScanXGovernance reset
8 Oct 2026CS and Compliance Officer resigns ScanXCompliance gap
~13–14 Oct 2026Q2/H1 FY2027: H1 loss about ₹0.03 Cr (headline cites a ₹0.07 Cr Q2 loss; figures inconsistent); H1 income ₹0.18 Cr vs ₹1.06 Cr; consolidated borrowings ₹5.52 Cr; cash ₹0.97 Cr WhalesbookFirst debt; continued losses

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Results by Segment: Other income, non-segment rose from INR 1.3 Mn in FY2024 to INR 12.2 Mn in FY2026.
Bacil Pharma Limited — Results by Segment
Series (INR Mn)FY2024FY2025FY2026
Other income, non-segment1.36.612.2
Segment pre-tax result-0.64.19.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BSE corporate filings (via Business Standard/Capital Market, ScanX/Dhan, Whalesbook, Groww, Vogue Commercial, Tiger Brokers summaries)
  2. Bacil Pharma Annual Report FY2025: Directors' Report and MD&A (via IndiaInfoline)
  3. FY2026 audited results, 22 May 2026 (via Capital Market/HDFC Securities and ScanX)
  4. Q1 FY2027 results, 12 Aug 2026 (Business Standard): Q2/H1 FY2027 results, Oct 2026 (Whalesbook)
  5. 39th AGM scrutinizer report, 23–24 Sep 2026 (ScanX)
  6. IndiaInfoline standalone balance sheet FY2022–FY2025: Screener.in P&L FY2015–FY2026 · Tickertape income history FY2015–FY2023 · Fyers P&L
  7. MCA master data via InstaFinancials, InsiderBiz, Companydetails.in, TheCompanyCheck
  8. Ownership: Simply Wall St, Angel One, Torus Digital, Whalesbook SAST reports
  9. Market data: Value Research, ICICI Direct, IIFL, HDFC Sky, Business Standard, MarketInOut, Trendlyne, Nirmal Bang, ScanX

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.